133 related articles for article (PubMed ID: 35081490)
1. Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?
Nasrallah GK
EBioMedicine; 2022 Feb; 76():103831. PubMed ID: 35081490
[No Abstract] [Full Text] [Related]
2. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients.
Smits VAJ; Hernández-Carralero E; Paz-Cabrera MC; Cabrera E; Hernández-Reyes Y; Hernández-Fernaud JR; Gillespie DA; Salido E; Hernández-Porto M; Freire R
Biochem Biophys Res Commun; 2021 Mar; 543():45-49. PubMed ID: 33515911
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD4 T Cells Elicited by Endemic Coronaviruses Display Vast Disparities in Abundance and Functional Potential Linked to Antigen Specificity and Age.
Richards KA; Glover M; Crawford JC; Thomas PG; White C; Sant AJ
J Infect Dis; 2021 May; 223(9):1555-1563. PubMed ID: 33556959
[TBL] [Abstract][Full Text] [Related]
5. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
Aguilar-Bretones M; Westerhuis BM; Raadsen MP; de Bruin E; Chandler FD; Okba NM; Haagmans BL; Langerak T; Endeman H; van den Akker JP; Gommers DA; van Gorp EC; GeurtsvanKessel CH; de Vries RD; Fouchier RA; Rockx BH; Koopmans MP; van Nierop GP
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34499051
[TBL] [Abstract][Full Text] [Related]
6. How kids' immune systems can evade COVID.
Nogrady B
Nature; 2020 Dec; 588(7838):382. PubMed ID: 33303982
[No Abstract] [Full Text] [Related]
7. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
Szymczak A; Jędruchniewicz N; Torelli A; Kaczmarzyk-Radka A; Coluccio R; Kłak M; Konieczny A; Ferenc S; Witkiewicz W; Montomoli E; Miernikiewicz P; Bąchor R; Dąbrowska K
J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34816794
[TBL] [Abstract][Full Text] [Related]
8. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088
[TBL] [Abstract][Full Text] [Related]
9. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.
Zedan HT; Nasrallah GK
EBioMedicine; 2021 Sep; 71():103580. PubMed ID: 34525435
[No Abstract] [Full Text] [Related]
10. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
[TBL] [Abstract][Full Text] [Related]
11. Development, production and characterization of SARS-CoV-2 virus-like particles (Coronaviridae:
Latyshev OE; Zaykova ON; Eliseeva OV; Savochkina TE; Chernoryzh YY; Syroeshkin AV; Petrov GV; Vorkunova GK; Larichev VF; Fediakina IT; Cherepushkin SA; Tsibezov VV; Yuzhakova KA; Kulikova NY; Lebedeva VV; Yakunin DY; Kozlova AA; Baranets MS; Yurlov KI; Lesnova EI; Grebennikova TV
Vopr Virusol; 2024 May; 69(2):175-186. PubMed ID: 38843023
[TBL] [Abstract][Full Text] [Related]
12. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
13. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.
Galipeau Y; Siragam V; Laroche G; Marion E; Greig M; McGuinty M; Booth RA; Durocher Y; Cuperlovic-Culf M; Bennett SAL; Crawley AM; Giguère PM; Cooper C; Langlois MA
EBioMedicine; 2021 Dec; 74():103700. PubMed ID: 34861490
[TBL] [Abstract][Full Text] [Related]
14. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
Tajuelo A; López-Siles M; Más V; Pérez-Romero P; Aguado JM; Briz V; McConnell MJ; Martín-Galiano AJ; López D
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328398
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
[TBL] [Abstract][Full Text] [Related]
16. Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week.
Troyano-Hernáez P; Reinosa R; Holguín Á
Viruses; 2021 Feb; 13(2):. PubMed ID: 33557213
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of Antibodies to Various Antigens of the SARS-CoV-2 Coronavirus in Patients with Confirmed COVID-19 Infection.
Aleshkin AV; Novikova LI; Bochkareva SS; Kombarova SY; Lebedin YS; Vorob'ev AM; Mekhtiev ER; Zul'karneev ER; Laishevtsev AI; Karaulov AV
Bull Exp Biol Med; 2021 May; 171(2):230-233. PubMed ID: 34173107
[TBL] [Abstract][Full Text] [Related]
18. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.
Wratil PR; Schmacke NA; Karakoc B; Dulovic A; Junker D; Becker M; Rothbauer U; Osterman A; Spaeth PM; Ruhle A; Gapp M; Schneider S; Muenchhoff M; Hellmuth JC; Scherer C; Mayerle J; Reincke M; Behr J; Kääb S; Zwissler B; von Bergwelt-Baildon M; Eberle J; Kaderali L; Schneiderhan-Marra N; Hornung V; Keppler OT
Cell Rep; 2021 Dec; 37(13):110169. PubMed ID: 34932974
[TBL] [Abstract][Full Text] [Related]
19. Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients.
Thieme CJ; Anft M; Paniskaki K; Blazquez-Navarro A; Doevelaar A; Seibert FS; Hoelzer B; Konik MJ; Berger MM; Brenner T; Tempfer C; Watzl C; Meister TL; Pfaender S; Steinmann E; Dolff S; Dittmer U; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Cell Rep Med; 2020 Sep; 1(6):100092. PubMed ID: 32904468
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Béguelin A
Rev Med Suisse; 2021 Jan; 17(723):234. PubMed ID: 33507668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
